
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics is a promising medical diagnostics technology company with strong potential for growth due to its innovative products, EsoCheck and EsoGuard, which have already received support from leading GI specialty associations. Though the company's current revenue is low, it is expected to increase significantly in the coming years and the recent Q4 results have exceeded expectations. With a strong balance sheet and plans for commercialization and regulatory approvals, Lucid is well-positioned for future success and its progress with Medicare is a potential catalyst for further growth. However, there are risks to consider, including liquidity concerns and the potential for product failure or regulatory hurdles.
Bears say
Lucid Diagnostics is poised for potential growth with the expected Medicare coverage of their EsoGuard product, but analysts still acknowledge the long road ahead for commercialization and growth in the billion dollar market potential. The recent Contractor Advisory Committee meeting and upcoming publication of the Draft LCD will likely help pave the way for mid-2026 coverage, but the risks associated with entering a crowded market should be closely considered.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares